Halozyme stock falls 2.34% after strong quarterly growth

Halozyme stock fell 2.34 percent to USD 112.44 on Nasdaq on September 23, 2026, at 4:00 p.m. ET. The move followed a period of strong operating growth, with second-quarter revenue reaching USD 481 million.

Q2 revenue rises 47.7 percent

According to MarketBeat, Halozyme reported USD 481 million of revenue in Q2 2026, up 47.7 percent from the same quarter a year earlier. The company also posted EPS of USD 2.28 against a consensus estimate of USD 1.79, a USD 0.49 beat.

The revenue figure gives the stock a fundamental counterweight to its daily decline. It also places the latest quarter well above the USD 402.28 million consensus revenue estimate cited by MarketBeat for Q2 2026.

Guidance meets new financing

Fiscal 2026 EPS guidance is USD 8.65 to USD 9.00, according to MarketBeat. That range is the key earnings benchmark after the company delivered USD 2.28 EPS in Q2 2026.

Financing has also become part of the investment picture. PR Newswire reported on September 17, 2026, that Halozyme priced USD 1.3 billion of 1.50 percent convertible senior notes due 2033. The offering was larger than the USD 1.05 billion proposal announced on September 16, 2026.

Stock remains below yearly high

At USD 112.44, Halozyme stock stood USD 4.40 below its 52-week high of USD 116.84 on September 23, 2026, a 3.77 percent gap. The 52-week low was USD 61.23, putting the latest price USD 51.21 above that level.

Market capitalization was USD 13,336,845,720 on the same date. The combination of a 47.7 percent quarterly revenue increase, USD 8.65 to USD 9.00 full-year EPS guidance and the USD 1.3 billion notes transaction leaves earnings delivery and financing execution as the main measurable reference points.

Halozyme stock trades at USD 112.44

Halozyme stock was trading at USD 112.44 on Nasdaq on September 23, 2026, at 4:00 p.m. ET, down 2.34 percent from the prior session.